AU2015263221A1 - Food compositions comprising tungsten (VI) salts - Google Patents
Food compositions comprising tungsten (VI) salts Download PDFInfo
- Publication number
- AU2015263221A1 AU2015263221A1 AU2015263221A AU2015263221A AU2015263221A1 AU 2015263221 A1 AU2015263221 A1 AU 2015263221A1 AU 2015263221 A AU2015263221 A AU 2015263221A AU 2015263221 A AU2015263221 A AU 2015263221A AU 2015263221 A1 AU2015263221 A1 AU 2015263221A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- tungsten
- use according
- salt
- cation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- FZFRVZDLZISPFJ-UHFFFAOYSA-N tungsten(6+) Chemical class [W+6] FZFRVZDLZISPFJ-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 27
- 230000035558 fertility Effects 0.000 claims abstract description 22
- 150000001768 cations Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 16
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 12
- 230000016087 ovulation Effects 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- -1 tungsten (VI) anion Chemical class 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002513 implantation Methods 0.000 claims description 9
- 239000008247 solid mixture Substances 0.000 claims description 9
- 210000000287 oocyte Anatomy 0.000 claims description 8
- 150000003657 tungsten Chemical class 0.000 claims description 8
- 235000008429 bread Nutrition 0.000 claims description 7
- 150000004683 dihydrates Chemical class 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 230000006735 deficit Effects 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- HFRYTYJESLXSNO-UHFFFAOYSA-N [Na+].[W+6] Chemical compound [Na+].[W+6] HFRYTYJESLXSNO-UHFFFAOYSA-N 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 235000020244 animal milk Nutrition 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 235000011194 food seasoning agent Nutrition 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 235000020245 plant milk Nutrition 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 239000004278 EU approved seasoning Substances 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 235000013527 bean curd Nutrition 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000014510 cooky Nutrition 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 235000015141 kefir Nutrition 0.000 claims description 2
- 235000013310 margarine Nutrition 0.000 claims description 2
- 239000003264 margarine Substances 0.000 claims description 2
- 235000020166 milkshake Nutrition 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 235000010603 pastilles Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 235000014214 soft drink Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007911 effervescent powder Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 41
- 238000011282 treatment Methods 0.000 description 26
- 230000035935 pregnancy Effects 0.000 description 18
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 14
- 208000000509 infertility Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000027758 ovulation cycle Effects 0.000 description 11
- 206010022489 Insulin Resistance Diseases 0.000 description 10
- 230000036512 infertility Effects 0.000 description 10
- 231100000535 infertility Toxicity 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019533 nutritive sweetener Nutrition 0.000 description 5
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 5
- QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000027046 diestrus Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000026234 pro-estrus Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 239000010937 tungsten Substances 0.000 description 4
- 238000011121 vaginal smear Methods 0.000 description 4
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 description 4
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 235000001667 Vitex agnus castus Nutrition 0.000 description 3
- 244000063464 Vitex agnus-castus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 230000012173 estrus Effects 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000005644 metestrus Effects 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000382455 Angelica sinensis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 201000005948 Donohue syndrome Diseases 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 2
- 101150029468 Irs2 gene Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101100287085 Mus musculus Irs2 gene Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 235000009108 Urtica dioica Nutrition 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 235000009347 chasteberry Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 2
- 230000001610 euglycemic effect Effects 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 235000008960 ketchup Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 210000000143 trophectoderm cell Anatomy 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007320 Avena fatua Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000169597 Chamaelirium luteum Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000033206 Early menarche Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000030271 Fetal Nutrition disease Diseases 0.000 description 1
- 206010016862 Foetal malnutrition Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 241001425930 Latina Species 0.000 description 1
- 208000035369 Leprechaunism Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 235000005373 Uvularia sessilifolia Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000009588 dong quai Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000012799 wholemeal bread Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940006486 zinc cation Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/60—Salad dressings; Mayonnaise; Ketchup
- A23L27/63—Ketchup
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to food compositions comprising tungsten (VI) salts and to the production thereof, for stimulating and normal reproduction and fertility in a non-diabetic female mammal.
Description
1
DESCRIPTION “Food compositions comprising tungsten (VI) salts”
The present invention relates to the use of tungsten (VI) salts for the preparation of food compositions, as well as to said food compositions, particularly for favoring normal reproduction and fertility in a non-diabetic female mammal.
PRIOR ART
Fertility in mammals is a multistage process that is not totally efficient naturally. Factors such as age, eating habits or life style, among others, modulate the success of this process. In this sense, it is known for example that pregnancy rate in women 20 to 24 years of age is about 86%, while it diminishes to 50% in women 35 to 32 years of age [Management of the Infertile Woman by Helen A. Carcio; The Fertility Sourcebook by M. Sara Rosenthal, ASAS Summary of FAIR 2012], Other factors such as overweight or underweight are also responsible for delays in achieving pregnancy naturally or even for the impossibility in achieving same [Fertil Steril 2013;100:631-7\. It is estimated that about 66% of couples do not conceive naturally during the first 3 months of unprotected sexual intercourse. This figure decreases to 15% of couples in the course of the first year of unprotected sexual intercourse. Infertility is defined (WHO, ASRM, NICE) as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The term “subfertility” has also been coined, particularly in Europe, to define those couples with any form or degree of reduced fertility leading to delay in conception [Gnoth C et al Definition and prevalence of subfertility and infertility, Human reproduction 2005;20(5):1144-1147\.
The main causes of infertility among women include ovulatory dysfunctions, pathologies of the reproductive tract, reduced oocyte quality and follicular depletion inherent to aging. However, there is also a considerable percentage of women with unexplained infertility, also referred to as idiopathic infertility, one of the possible causes of which relates to deficiencies in the implantation process. 2
Follicular development, ovulation, migration of immature egg (oocyte), as well as subsequent conception and zygote implantation on the uterine wall is regulated by hormonal secretions of certain endocrine organs such as the pituitary gland, the hypothalamus and the thyroid gland, for example. Among the different biological causes of infertility in women, causes linked to disorders in the hormonal stimuli regulating this whole process can also be pointed out.
Different treatments for female infertility including, among others, the administration of medicinal products for treating hormonal problems involving ovulation disruption, are known. Likewise, some beneficial effects have been postulated with various treatments based on taking vitamin supplements, particularly vitamin B, vitamin C, vitamin E and folic acid, mineral supplements such as selenium, zinc or iron complexes or salts, essential fatty acids (omega-3), as well as extracts from plants such as chaste tree {Vitex agnus-castus), damiana, licorice, red clover flower, chasteberry, black cohosh, dong quai (Angelica sinensis), wild yam or sweet potato {Dioscorea villosa), false unicorn root, green tea, nettles (Urtica dioica), wild oats (Avena sativa), dandelion (Taraxacum officinale), etc., although the efficacy has not been clearly demonstrated in any of these treatments.
The percentage of pregnancies achieved by means of the aforementioned treatments has limitations. In this sense, for example, it has been observed that treatment of women with irregular or no ovulation by means of administering clomiphene citrate, a drug of the stilbene family, allows restoring ovulation in a high percentage, but the pregnancy rate remains low, equal to or less than about 50%.
In vitro fertilization treatments are very effective in the oocyte fertilization step. However, the embryo implantation rate on the uterine wall is low. This promotes multiple embryo transfers per each in vitro fertilization cycle, with the consequence of a higher percentage of risky multiple pregnancies.
Finally, it is known that metabolic disorders such as diabetes or obesity entail a limitation of fertility. It is known that partial or complete recovery of glycemia, insulinemia and/or body weight in diabetic or obese female mice with damaged reproductive function, involves an improvement in fertility. 3
Different pharmacological treatments, such as metformin or tungsten (VI) salts, or even life style changes, have been shown to improve diabetes or insulin disorders, such as insulin deficiency or insulin resistance, for example, completely or partially recovering the reproductive function, when the infertility is due to diabetes or insulin disorders.
In the specific case of sodium tungstate, it is known that rats with diabetes and insulinopenia induced by the injection of streptozotocin partially recover circulating insulin levels after a prolonged treatment (10 weeks) with sodium tungstate as a result of partially reversing diabetes. Subsequently, when the female rats partially recovered from diabetes mate with healthy male rats, it is observed that, parallel to the partial recovery from diabetes, they have partially recovered their reproductive capacity. Particularly, it is observed that the percentage of births with respect to the number of positive curettages in female mice which had partially recovered from diabetes after treatment with sodium tungstate increases to 66%, a percentage which is lower than non-diabetic female mice where the percentage is 100%. (cf. J. Ballester et. al., “Tungstate administration improves the sexual and reproductive function in female rats with streptozotocin-induced diabetes”, Human Reproduction, 2007, vol. 22, pp. 2128-2135). Nevertheless, the tungsten (VI) salts were neither observed nor postulated to have effect on non-diabetic female animals.
Tungsten is found in trace amounts in animals and plants. For example, tungsten content of up to a maximum of 100 mg/kg has been described in plants [Gbaruko B.C. & Igwe J.C. Global Tungsten: Occurrence, Chemistry, Environmental and Health Exposure Issues. Journal of Environmental Research 2007;1(1):27-32].
In view of the foregoing, despite the extensive research and progress in understanding and handling the reproductive process in mammals and particularly in humans, there are still many couples who do not benefit from the different approaches available today for increasing fertility as they are ineffective. Therefore, there is still a need to find new alternatives for improving natural reproductive efficiency and/or treating female infertility that provide greater efficacy. 4
DISCLOSURE OF THE INVENTION
It has now been found that the administration of a tungsten (VI) salt or a solvate of said salt is effective for favoring normal reproduction and fertility in a non-diabetic female mammal. Despite the fact that sodium tungstate was known to be able to partially reverse impairments in the reproductive function of diabetic female mice because it normalizes blood glucose levels, the possibility of sodium tungstate having an effect on the function of the female reproductive system in non-diabetic female mammals, favoring normal reproduction and fertility, has not been described nor suggested. A first aspect of the present invention therefore relates to the use of a tungsten (VI) salt or a solvate thereof for the preparation of a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal. A second aspect of the present invention relates to a food composition which comprises a tungsten (VI) salt or a solvate thereof at a concentration greater than 100 mg/kg.
DETAILED DISCLOSURE OF THE INVENTION
As indicated above, according to a first aspect the present invention relates to the use of a tungsten (VI) salt or a solvate thereof for the preparation of a food composition for favoring and/or contributing to normal reproduction and fertility in a non-diabetic female mammal.
In the context of the present invention, the term “food composition” would encompass any solid or liquid tungsten (VI) salt-enriched food, as well as any nutritional supplement or complement containing at least one tungsten (VI) salt.
The term “favoring normal reproduction and fertility” or “contributing to normal reproduction and fertility” refers to contributing to normal reproduction and fertility or improving normal reproduction and fertility (reducing the times for achieving pregnancy), “normal reproduction and fertility” being understood as a state of fertility 5 in which pregnancy is achieved following the definitions provided above: * in a subfertility situation: pregnancy is achieved in a period of 12 months of regular, unprotected sexual intercourse; and * in an infertility situation: pregnancy is achieved after a period 12 months of regular, unprotected sexual intercourse. The need to restore and/or promote ovulation, improve oocyte and embryo quality, increase zygote implantation on the uterine wall, regulate hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia are included herein.
According to a particular embodiment, the food composition of the invention contains a total concentration (i.e., the sum of all tungsten (VI) salts contained in the composition) of tungsten salts of at least 100 mg/kg; according to other particular embodiments, said total concentration is preferably of at least 150 mg/kg, at least 200 mg/kg, at least 250 mg/kg, at least 300 mg/kg, at least 350 mg/kg, at least 400 mg/kg, at least 450 mg/kg, at least 500 mg/kg, at least 550 mg/kg, at least 600 mg/kg, at least 650 mg/kg, at least 700 mg/kg, at least 750 mg/kg, at least 800 mg/kg, at least 850 mg/kg, at least 900 mg/kg or at least 850 mg/kg.
According to another particular embodiment, the total concentration of tungsten (VI) salts is equal to or less than 1000 mg/kg.
The female mammal in the context of the present invention can be any mammal, including, but not limited to, humans, mice, rats, rabbits, dogs, cats, guinea pigs, hamsters, cows, horses, pigs, sheep, goats, etc.
According to a particular embodiment, the female mammal is a human. According to another particular embodiment, the food composition will be suitable for the administration of tungsten salts in a daily dose between 0.001 mg per kg of body weight of the female mammal (hereinafter, mg/kg/day) and the maximum tolerated dose for the corresponding female mammal species.
According to a further particular embodiment, the maximum daily dose will be 1000 6 mg/kg/day; according to additional particular embodiments, the administration would be carried out in doses of at least 0.001 mg/kg/day, at least 0.01 mg/kg/day, at least 0.1 mg/kg/day, at least 0.5 mg/kg/day, at least 1 mg/kg/day, at least 10 mg/kg/day, at least 25 mg/kg/day, at least 50 mg/kg/day, at least 100 mg/kg/day, at least 200 mg/kg/day, at least 300 mg/kg/day, at least 400 mg/kg/day, at least 500 mg/kg/day, at least 600 mg/kg/day, at least 700 mg/kg/day, at least 800 mg/kg/day or at least 900 mg/kg/day.
The tungsten salt generally comprises a tungsten (VI) anion and a dietetically or pharmaceutically acceptable cation. The cation is preferably an alkaline or alkaline earth cation. The cation is more preferably selected from the group consisting of sodium, potassium, magnesium, calcium and zinc. According to a particular embodiment, the tungsten (VI) salt is the tungsten (VI) sodium salt.
The tungsten (VI) anion is in turn preferably selected from the list consisting of W042", HW04", W2072- and HW207". The anion is preferably W042'.
According to a particular embodiment, the salt is in the form of a solvate; the solvate is preferably a hydrate, more specifically a dihydrate.
All the features listed individually for different elements of the invention can be combined with one another, all the possible combinations being included within the scope of the present invention. For example, according to a preferred embodiment the solvate of the tungsten (VI) salt is a dihydrate and the cation is a sodium cation. Similarly, the rest of the possible combinations is also intended to be included within the scope of the present invention.
The food composition can be a liquid composition, i.e., a beverage, according to terms most generally used in the society. In the context of the present invention, such liquid composition includes, but is not limited to, any beverage selected from the group consisting of animal or plant milk, as well as any derivative thereof, such as for example, milk shakes, yogurt, kefir, etc.; fruit and/or vegetable juices; still water or sparkling water, or flavored or sweetened water or beverages (by means of nutritive sweeteners (sucrose, fructose...) or artificial sweeteners); seasonings, such as for example, any salsa, dressing, ketchup, oil, vinegar or vinegar preparations; 7 alcoholic beverages of any type; tea, coffee; as well as all types of refreshing beverages or soft drinks, or energizing beverages.
The food composition can also be a solid composition. Such solid composition can, for example, be selected from, but is not limited to, the group consisting of animal or plant milk derivatives, such as cheese, butter, margarine and tofu; any type of bread, including fresh, packaged or frozen bread, sliced bread, wholemeal bread, spiced bread, sweet bread, salty bread, etc; pasta prepared from any cereal flour, such as wheat or semolina flour (macaroni, spaghetti, noodles, etc); baked goods, including cakes, cookies, muffins, doughnuts, etc.; infusions, tea or coffee, in bulk or in sachets, for preparing beverages; jellies, candies, including gummy candies, better known as “soft fruit candies”; as well as any type of solid seasoning, for example, oregano, salt, coriander, parsley, basil, etc, or mixtures thereof.
Finally, the food composition can also be a nutritional, dietary or food supplement or complement, any of these terms being used in the context of the present invention in an equivalent manner. These terms are normally used for compositions consumed orally, which contain an ingredient intended for complementing the diet, in the case of the present invention, the tungsten (VI) salt/salts. They shall never replace a conventional food, or be the only component of a meal or of the diet. They can be found in different presentations, such as pastilles, pills, tablets, capsules, soft gelatin capsules, gelatin capsules, wafers, effervescent tablets, liquids (solution, suspension, syrup), granules and powders, all of which are included as particular embodiments within the scope of the present invention. Dietetically or pharmaceutically acceptable excipients are obvious for the skilled person for obtaining any of the preceding presentations, and they are included within the scope of the present invention.
According to a particular embodiment, any of the preceding food compositions (solid composition, liquid composition or nutritional supplement/complement) comprises in their composition at least one nutritive sweetener, such as sucrose or fructose. Ingestion of these nutritive sweeteners must be controlled and limited in diabetic patients, therefore a food composition including such nutritive sweetener would be contraindicated in diabetic mammals or would at least be taken into account in controlling their diet. 8
According to a particular embodiment, the non-diabetic female mammal is selected from the group consisting of female mammals that require restoring and/or promoting ovulation, improving oocyte and embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.
According to another particular embodiment, the non-diabetic female mammal is selected from the group consisting of female mammals having insulin resistance (also known as resistance to insulin or insulinic resistance); when insulin resistance occurs together with hyperglycemia, it can lead to the development of diabetes, nevertheless insulin resistance alone does not lead to a diabetic condition. The female mammals having insulin resistance are preferably selected from the group consisting of female mammals having one or more of the following conditions: obesity or overweight, metabolic syndrome, prediabetes, polycystic ovarian syndrome, hypertension, heart disease, hyperlipidemias or dyslipidemia, hyperthyroidism, hyperparathyroidism, hyperleptinemia or leptin resistance, sedentary life style, eating disorders, obstructive sleep apnea syndrome, fetal malnutrition, Prader-Willi syndrome, Rabson-Mendenhall syndrome, fatty liver, leprechaunism, pathologies associated with excessive glucocorticoid secretion (e.g., acromegaly), insulin resistance caused by pharmacological treatments (e.g., glucocorticoids, thiazide diuretics, beta-blockers), stress or early menarche [Egas Be jar, Daniela et.al Insulinorresistencia/lnsulin resistance. Medicina (Guayaquil);10(2):159-166, April 2005; Graves, Thomas K. WHY ISN’T THIS INSULIN WORKING? Western Veterinary Conference 2013 (SA113); Ximena Gaete V. Adelanto de la pubertad en Chile y el mundo. Rev Chil Pediatr 77 (5); 456-465, 2006; Leszek Szablewski Glucose Homeostasis and Insulin Resistance (elSBN: 978-1-60805-) Bentham e-books]. Many of these indications have been described to be unrelated to infertility, including prediabetes [Acta Diab. Latina 4, 507, 1967\.
Another aspect of the present invention relates to a food composition which comprises tungsten (VI) salt or salts or a solvate thereof at a concentration of at least 9 100 mg/kg. According to particular embodiments, the tungsten (VI) salt or salts are comprised in the composition at concentrations of at least 150 mg/kg, at least 200 mg/kg, at least 250 mg/kg, at least 300 mg/kg, at least 350 mg/kg, at least 400 mg/kg, at least 450 mg/kg, at least 500 mg/kg, at least 550 mg/kg, at least 600 mg/kg, at least 650 mg/kg, at least 700 mg/kg, at least 750 mg/kg, at least 800 mg/kg, at least 850 mg/kg, at least 900 mg/kg or at least 850 mg/kg.
All the definitions and preferred meanings provided above in relation to the first aspect of the invention are applicable to this second aspect of the invention. Therefore, for example, the tungsten (VI) salt will comprise a tungsten (VI) anion and a dietetically or pharmaceutically acceptable cation, which will preferably be an alkaline or alkaline earth cation, even more preferably a sodium, potassium, magnesium and calcium and zinc cation. Particularly, the salt will be tungsten (VI) sodium salt. The tungsten (VI) anion is once again selected from W042", HW04“, W2072- and HW207" ions, preferably W042-, and in the case of being presented in the form of a solvate, the solvate will preferably be a hydrate, more specifically a dihydrate. The rest of the particular embodiments provided above for the first aspect also relate to this second aspect.
The food composition of the second aspect of the invention can be a liquid composition or beverage, a solid composition or a nutritional supplement or complement (also referred to as dietary or food supplement or complement).
The liquid composition has already been defined above in relation to the first aspect of the invention, and all the preferred embodiments are also applicable to this second aspect of the invention.
Likewise, the solid composition has been defined above in relation to the first aspect of the invention, and all the preferred embodiments are also applicable to this second aspect of the invention.
Similarly, the nutritional supplement or complement (or dietary or food supplement or complement) has been defined above in relation to the first aspect of the invention, and all the preferred embodiments are also applicable to this second aspect of the invention. 10
The composition preferably comprises a nutritive sweetener, such as sucrose or fructose. A series of non-limiting, illustrative examples of the present invention are included below.
EXAMPLES
Example 1. Description of the animal model (IRS2 -/- female mice)
The mouse model used for determining the activity of tungsten (VI) salts for favoring normal reproduction and fertility is an Irs2 gene knock-out mouse, IRS27 [Burks et. al., “IRS-2 pathways integrate female reproduction and energy homeostasis”, Nature, 2000, vol. 407, pp. 377-382\. Irs2 gene deletion translates into a clear sexual dimorphism in relation to fertility and carbohydrate metabolism.
The male mice of this model have insulin resistance and severe hyperglycemia that started at an early age. In contrast, the female mice remain relatively euglycemic at an early age and develop slight insulin resistance which remains until a later age (4-5 months). IRS2_/" female mice at an early age, about 10 weeks old, show a low follicular development and persistent anovulation, accompanied by the absence of estrous cycle in most mice. The pregnancy rate in IRS2_/" female mice is 9% compared to the rate of 100% in IRSwt (IRS-2+/+ wild type) female mice. Given that female mice at these ages remain euglycemic and that they only develop slight insulin resistance, the profound impairment in fertility is not a direct result of anomalies in glucose metabolism.
Example 2. Ovulation, implantation and pregnancy study A. Animals
Ten IRS2_/" female mice of ages comprised between 6 and 8 weeks.
Six “wild-type” (^82^) male mice of ages comprised between 6 and 8 weeks. 11
The female and male mice were housed separately in normal conditions, i.e., a 12h light/darkness cycle and controlled temperature and humidity. The animals were fed at will (also referred to as ad libitum) with a standard feed diet. B. Method
Pre-treatment phase
After an acclimatization period, the IRS27 female mice were housed in groups of 4-6 mice/cage. Tungstate salt-free drinking water was administered to the animals during the pre-treatment phase (2 weeks).
Treatment phase
Sodium tungstate was administered in the drinking water (ad libitum) by means of a solution of 2 mg/ml of sodium tungstate dihydrate (marketed by Carlo Erba) in distilled water after the pre-treatment phase (day 0 of treatment) and up to 4 weeks before sacrificing the animals. The daily dose of sodium tungstate ingested by the mice was about 180 mg/kg of body weight.
Mating
After the first three weeks of treatment, the IRS2"7" female mice were housed in cages in pairs together with a ^82^ male mouse continuously.
The mice were observed daily to look for signs of pregnancy or birth.
After 4 weeks, the male mice were exchanged between the cages and they were kept therein for another 4 weeks.
The administration of tungstate was maintained for 8 weeks in which male and female mice were housed together. After these 8 weeks, treatment was withdrawn and the male and female mice were housed together for 4 additional weeks.
Sacrifice 12
After this period, the female mice were sacrificed and biopsy was carried out to look for indications of pregnancy. C. Results
Results of the ovulation study
During the pre-treatment period and during the first 3 weeks of treatment, vaginal smears were performed in 6 randomly chosen female mice on days -8; -5; -2; -1; 7; 8; 14; 15 and 22, to determine the phase of the estrous cycle they were in.
Between 1 and 2 ml of saline solution was introduced into the vagina of the mice with a Pasteur pipette. Vaginal exudate was collected with the same pipette and spread on a slide. Once air-dried, it was fixed and stained with the Papanicolau technique.
The Papanicolau technique comprises staining the vaginal smears fixed on the slide in the following manner: -10 immersions in 50% v/v alcohol; - Immersing in Harris hematoxylin solution for 3 minutes; - Rinsing with running water; -10 immersions in acid alcohol (1% hydrochloric acid); - Rinsing with running water; -10 immersions in 95% v/v alcohol; - Immersing in OG-6 solution for 30 seconds; -10 immersions in 96% v/v alcohol; - Immersing in eosin solution for 1 minute; -10 immersions in 96% v/v alcohol; -10 immersions in 86% v/v alcohol; and -10 immersions in xylol
The preparations were analyzed by trained staff using a coding in a single-blind manner for eliminating observer bias.
The samples were identified in the following phases: diestrus, proestrus, estrus, metestrus, anestrus or non-evaluable. The cyclical nature of the four phases in 13 periods of 4 to 6 days are indicative of a normal estrous cycle, whereas the absence of this cyclical nature and the persistence in anestrus, diestrus or proestrus phases are indicative of the absence of estrous cycle. 5 Of the 10 female mice subjected to study, Table 1 summarizes the phases of the estrous cycle in the vaginal smears performed in 6 of these IRS2_/" female mice.
Table 1
Mouse Time (davs) No. -8 -5 -2 -1 7 8 14 15 22 72 A A P D E E-M E E A 898 D D P P E E E-M M M 926 D D P P E-M E-M D E P 928 D-P D P P E E E-M M A 942 A D P P E E-M E-M A D 972 D D P M M D D 10 The phases of the estrous cycle are the following: A: Anestrus; D: Diestrus; P: Proestrus; E: Estrus; and M: Metestrus.
The phases of the estrous cycle found in the vaginal smears of the IRS2_/" female mice of Table 1 show that during the pre-treatment period all the mice were in the 15 proestrus (P) or diestrus (D) phase, i.e., with the absence of estrous cycle.
However, after starting the administration of tungstate, it is observed that the IRS2_/" female mice are in the late phases of estrous cycle, i.e., estrus (E) and metestrus (M) phases, which is indicative of the recovery of a normal estrous cycle. 20
These results indicate that the administration of a tungsten (VI) salt allows quick recovery (on the seventh day of treatment) of the estrous cycle in infertile, nondiabetic IRS2_/" female mice in 100% of analyzed mice. 14
Results of the implantation and pregnancy study
After the cross-breeding period of the method of section B, the female mice were sacrificed and biopsies were carried out to look for indications of pregnancy.
Table 2 summarizes the age at the time of treatment, whether or not there was pregnancy and the number of embryos per female mouse.
Table 2
Mouse No. Age (months) at the start of Pregnancy Number of embryos implanted or young born treatment cross-breeding 72 10 12 YES 1 young 942 10 12 YES 8 young 928 10 12 YES 7 embryos 931 10 12 YES 3 young 898 10 12 YES 7 embryos 900 10 12 NO - 921 10 12 YES 6 embryos 926 10 12 YES 8 young 972 8 10 NO - 973 8 10 YES 7 embryos
The results of Table 2 show that while the pregnancy rate in untreated IRS2_/' female mice is 9%, the pregnancy rate in IRS2_/" female mice treated with tungstate increases to 80%. 15 Furthermore, these results also show that the mean of young/implanted embryos per pregnant female mouse is about 5, a number which can be considered comparable 15 to the number of young of a female mouse.
Therefore, the results of Tables 1 and 2 demonstrate that a tungsten (VI) salt is an effective treatment for recovering ovulation and/or increasing oocyte implantation. Therefore, the administration of a tungsten (VI) salt as defined in the present invention is effective for the treatment of infertility in non-diabetic female mammals.
Example 3. Glvcemia and body weight study A. Animals
Six IRS2 Λ female mice of ages comprised between 6 and 8 weeks.
The female mice were housed in normal conditions, i.e., a 12h light/darkness cycle and controlled temperature and humidity. The animals were fed at will (also referred to as ad libitum) with a standard feed diet. B. Method
Treatment phase
After an acclimatization period, sodium tungstate was administered in the drinking water (ad libitum) by means of a solution of 2 mg/ml of sodium tungstate dihydrate (marketed by Carlo Erba) in distilled water after the pre-treatment phase (day 0 of treatment) and for 12 days. C. Results
The body weight was monitored on days 0, 2, 5, 7, 9 and 12 of the treatment period, and the blood glucose was determined after 6 hours of fasting on each of the aforementioned days by means of drawing blood from the tail vein and with a glucose sensor (AccuTrend glucose sensor, Roche, Mannheim, Germany).
Table 3 summarizes the glycemic levels expressed in mg/dl, and Table 4 summarizes the body weight of the mice under study expressed in grams. 16
Table 3
Glycemia (mg/dl) R1327 R1345 R1347 R1354 R1376 R1381 Average Day 0 146 129 115 126 141 112 128.17 Day 2 136 128 118 110 105 107 117.33 Day 5 125 142 114 111 137 105 122.33 Day 7 140 110 106 89 133 135 118.83 Day 9 125 153 109 108 131 125 125.17 Day 12 136 116 111 86 123 141 118.83
Table 4
Body weight (g) 1327 1345 1347 1354 1376 1381 Average Day 0 22.7 15.33 18.21 16.5 13.99 15.45 17.03 Day 2 22.9 14.84 18.98 17.01 14.18 16.04 17.33 Day 5 22.61 14.89 18.2 16.61 13.79 15.72 16.97 Day 7 22.42 15.07 17.81 16.35 13.74 15.66 16.84 Day 9 22.85 15.56 17.9 16.89 14.5 16.39 17.35 Day 12 23.15 15.91 18.24 17.19 14.92 16.89 17.72 5
The results of Tables 3 and 4 show that during the administration of sodium tungstate no variations were observed in the body weight or in the glycemia in the first 12 days of treatment, the same period in which ovulation is successfully reestablished in the tested female mice from day 7 of treatment (cf. Table 1). 10
Therefore, the results of Tables 1 to 4 demonstrate that a tungsten (VI) salt is a treatment effective for recovering ovulation and/or increasing oocyte implantation, regardless of the changes in body weight and in carbohydrate metabolism. It is therefore demonstrated that the administration of a tungsten (VI) salt as defined in 15 the present invention or a composition containing such tungsten (VI) salt has a direct 17 effect on the female reproductive system and is therefore effective for favoring normal reproduction and fertility in non-diabetic female mammals.
Example 4. Endometrial embryonic adhesion study A. Model
An “in vitro" human-human embryonic adhesion model made up the HEC1-A endometrial cell line and the JEG-3 trophectoderm cell line was used to determine the effect of sodium tungstate on endometrial receptivity.
The JEG-3 cell line which simulates the trophectoderm cells of a human embryo are cells that grow in monolayers in the laboratory using low adherence plates and are capable of forming spheroids simulating the human embryo; this is one of the most widely used cell lines for conducting in vitro embryonic adhesion assay. B. Method
The cell lines were commercially purchased (American Type Culture Collection (ATCC); Rockville, MD, USA) for conducting the endometrial embryonic adhesion experiments. They were thawed and expanded in 4 passes for obtaining sufficient cells to perform all the assays.
The HEC1-A cells were plated in 24-well plates and cultured with McCoy 5A culture medium supplemented with 10% fetal bovine serum and 0.1% antibiotics (fungizone and penicillin), until reaching 90% confluence. After reaching the confluence, there was added to the culture medium sodium tungstate at a final concentration of 10 μΜ, as well as Withaferin A (as a control, a compound that prevents embryonic adhesion) or culture medium (baseline adhesion data), without any additional component, for 24 hours.
The JEG-3 cells were plated in low adherent plates with Eagle’s minimal essential medium (EMEM) culture medium supplemented with 10% fetal bovine serum and 0.1% antibiotics (fungizone and penicillin). Twenty-four hours before the adhesion assay, the JEG-3 trophoblast spheroids were formed from this culture. To that end, 18 JEG-3 cells in the medium described above were suspended in an Erlenmeyer flask under stirring at a concentration of 6x105 cells/6 ml. The resulting spheroids were collected for the adhesion assay. 5 For the adhesion assay, 24 hours after culturing the HEC-1A cells with culture medium adding sodium tungstate, Withaferin A or without adding any treatment, the culture medium was changed with fresh culture medium without treatments under study. The trophectoderm spheroids were added onto the monolayer of HEC-1A cells, placing 6 to 10 spheroids per well. The adhesion of the spheroids was 10 measured after 60 minutes, counting spheroid that was floating in the culture medium as non-adhered spheroid and spheroid that was not floating as adhered spheroid. The examination was conducted with an inverted microscope (Nikon Diaphot 300; Nikon Corp., Tokyo, Japan). The assay was conducted in triplicate. 15 C. Results
The results obtained are listed in Table 5. A higher percentage of embryonic adhesion was observed in the conditions in which the HEC-1A lines were treated with sodium tungstate with respect to those in which they were not treated. No 20 adhesion whatsoever is observed in cells treated with the negative control (C-), Withaferin A.
Table 5
Absolute adhesion rates Exp 1 Exp 2 Exp 3 Mean Baseline adhesion 12% 48% 31% 30% 10 μΜ sodium tungstate 31% 65% 35% 44% Withaferin A (C-) 0% 0% 0% 0% 25
PARTICULAR COMPOSITIONS OF THE INVENTION
Food compositions according to the invention are prepared below in an illustrative manner. They must in no way be interpreted as limiting the scope of the invention. 19
Example 5 A tungsten salt-enriched salad dressing is prepared. An amount of 25 mg of Na2W04 (100 mg/kg) is added to 250 grams of a commercially available dressing and it is mechanically stirred for 30 minutes.
Example 6 A tungsten salt-enriched ketchup-type salsa is prepared. To that end, 170 mg of CaW04 are added to 200 grams of commercially available ketchup and it is mechanically stirred for 1 hour.
Example 7 A tungsten salt-enriched milk is prepared. To that end, 1 kg of whole cow’s milk is provided, 150 mg of ZnW04 are added and it is mechanically stirred for 20 minutes. It is recommended to shake the packaging immediately before consumption.
Example 8 A tungsten salt-enriched fruit juice is prepared. Five-hundred mg of MgW04 are added to 1 kg of commercial juice and it is mechanically stirred for 10 minutes. It is recommended to shake the packaging immediately before consumption.
Example 9
Coated tablets with the following composition are prepared: PH200 Microcrystalline cellulose (diluent/gliding agent) 250.00 mg Colloidal anhydrous silica (gliding agent/adsorbent) 3.00 mg Magnesium stearate (lubricant) 5.00 mg Talc (lubricant) 7.00 mg
Opadry® white (Opadry® and-1-7000 White)(*) (coating film) 8.00 mg Sodium tungstate dihydrate 200.00 mg (*) mixture of hydroxypropylmethylcellulose, polyethylene glycol 6000 and 20 titanium dioxide (E-171)
Example 10 5 Effervescent tablets with the following composition are prepared:
Sorbitol, aspartame, sucralose and xylitol (sweeteners) 0.025mg per 10 mg Calcium carbonate 0.350 mg per 10 mg Citric acid (acidulant) 0.650 mg per 10 mg Sodium acid carbonate (acidity regulator) 0.350 mg per 10 mg 10 Orange flavoring 0.25 mg per 10 mg Tungsten salt
Example 11 15 Gelatin capsules with the following composition are prepared:
Nifedipine 6 mg Xanthan gum 5 mg Orange flavoring 0.3 mg Citric acid 0.4 mg 20 Gelucire 44/14 90 mg PH10 microcrystalline cellulose (diluent) 92.00 mg/capsule Sodium tungstate dihydrate 100.00 mg/capsule
Claims (34)
1. Use of a tungsten (VI) salt or a solvate thereof for the preparation of a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal.
2. Use according to claim 1, characterized in that the total concentration of tungsten salts in the composition is equal to or greater than 100 mg/kg.
3. Use according to any one of claims 1 and 2, characterized in that the mammal is a human.
4. Use according to claim 3, characterized in that the composition is administered in a daily dose between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the female mammal.
5. Use according to any one of claims 1 to 4, characterized in that the salt comprises a tungsten (VI) anion and a dietetically or pharmaceutically acceptable cation.
6. Use according to claim 5, characterized in that the cation is an alkaline or alkaline earth cation.
7. Use according to any one of claims 5 or 6, characterized in that the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.
8. Use according to any one of the preceding claims, characterized in that the tungsten (VI) salt is the tungsten (VI) sodium salt.
9. Use according to any one of claims 5 to 8, characterized in that the tungsten (VI) anion is selected from W042', HW04~, W2072” and HW207_ ions.
10. Use according to claim 9, characterized in that the anion is W042”.
11. Use according to any one of the preceding claims, characterized in that the solvate is a dihydrate.
12. Use according to claims 6 to 11, characterized in that the solvate of tungsten (VI) salt is a dihydrate and the cation is a sodium cation.
13. Use according to any one of the preceding claims, characterized in that the composition is a liquid composition or a beverage.
14. Use according to claim 13, characterized in that the liquid composition or beverage is selected from the group consisting of animal or plant milk as well as derivatives thereof, such as milk shakes, yogurt and kefir; fruit and/or vegetable juices; still water, sparkling water and flavored or sweetened water; seasonings; alcoholic beverages; tea; coffee; and refreshing beverages or soft drinks.
15. Use according to any one of claims 1 to 12, characterized in that the composition is a solid composition.
16. Use according to claim 15, characterized in that the solid composition is selected from animal or plant milk derivatives, such as cheese, butter, margarine and tofu; flours; breads; pasta; baked goods, including cakes and cookies; jellies, candies, soft fruit candies; infusions, tea or coffee; seasonings.
17. Use according to any one of claims 1 to 12, characterized in that the food composition is a nutritional supplement or complement.
18. Use according to claim 17, characterized in that it comprises at least one pharmaceutically acceptable excipient or carrier presented in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablet, solution, suspension, syrup or granules.
19. Use according to any one of the preceding claims, characterized in that the composition comprises sucrose.
20. Use according to any one of the preceding claims, characterized in that the non-diabetic female mammal is selected from the group of mammals that require restoring and/or promoting ovulation, improving oocyte or embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.
21. A food composition, characterized in that it comprises a tungsten (VI) salt or a solvate thereof at a concentration equal to or greater than 100 mg/kg.
22. The composition according to claim 21, characterized in that the salt comprises a tungsten (VI) anion and a dietetically or pharmaceutically acceptable cation.
23. The composition according to claim 22, characterized in that the cation is an alkaline or alkaline earth cation.
24. The composition according to any one of claims 22 and 23, characterized in that the cation is selected from the group consisting of sodium, potassium, magnesium and calcium and zinc.
25. The composition according to any one of claims 21 to 24, characterized in that the tungsten (VI) salt is the tungsten (VI) sodium salt.
26. The composition according to any one of claims 22 to 25, characterized in that the tungsten (VI) anion is selected from W042", HW04~, W2072" and HW207~ ions.
27. The composition according to claim 26, characterized in that the anion is W042-.
28. The composition according to any one of claims 21 to 27, characterized in that the solvate is a dihydrate.
29. The composition according to any one of claims 21 to 28, characterized in that the solvate of tungsten (VI) salt is a dihydrate and the cation is a sodium cation.
30. The composition according to any one of claims 21 to 29, characterized in that it is a liquid composition or a beverage, a solid composition or a nutritional supplement or complement.
31. The composition according to claim 30, characterized in that it is a liquid composition or a beverage as defined in claim 14.
32. The composition according to claim 30, characterized in that it is a solid composition as defined in claim 16.
33. The composition according to claim 30, characterized in that the food composition is a nutritional supplement or complement as defined in claim 18.
34. The composition according to any one of claims 21 to 33, characterized in that it comprises sucrose.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430747A ES2551828B1 (en) | 2014-05-21 | 2014-05-21 | Food compositions comprising tungsten salts (VI) |
ESP201430747 | 2014-05-21 | ||
PCT/ES2015/070399 WO2015177393A1 (en) | 2014-05-21 | 2015-05-21 | Food compositions comprising tungsten (vi) salts |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015263221A1 true AU2015263221A1 (en) | 2016-12-22 |
AU2015263221B2 AU2015263221B2 (en) | 2018-08-09 |
Family
ID=53524795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015263221A Active AU2015263221B2 (en) | 2014-05-21 | 2015-05-21 | Food compositions comprising tungsten (VI) salts |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR100545A1 (en) |
AU (1) | AU2015263221B2 (en) |
ES (1) | ES2551828B1 (en) |
NZ (1) | NZ726934A (en) |
TW (1) | TW201600022A (en) |
UY (1) | UY36133A (en) |
WO (1) | WO2015177393A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3173382T (en) * | 2014-07-21 | 2023-03-10 | Oxolife Sl | Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2108642B1 (en) * | 1995-07-26 | 1998-08-16 | Quimica Farm Bayer Sa | TUNGSTEN (VI) COMPOSITIONS FOR THE ORAL TREATMENT OF DIABETES MELLITUS. |
ES2187276B1 (en) * | 2001-05-16 | 2004-08-01 | Quimica Farmaceutica Bayer,S.A. | ORAL COMPOSITIONS FOR THE TREATMENT OF OBESUS AND NON-DIABETIC HUMANS. |
CN101237875B (en) * | 2005-07-29 | 2011-07-13 | 巴塞罗纳大学 | Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia |
CN101720937A (en) * | 2009-12-30 | 2010-06-09 | 林小平 | Nutriment containing phosphorus, vanadium, molybdenum and tungsten |
CN101744835A (en) * | 2009-12-30 | 2010-06-23 | 林小平 | Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system |
ES2478790B1 (en) * | 2013-01-22 | 2015-05-06 | Oxolife, S. L. | Use of tungsten salts (VI) for the treatment of female infertility in non-diabetic mammals |
WO2014200929A1 (en) * | 2013-06-10 | 2014-12-18 | The Regents Of The University Of California | Tungstate treatment of the dysbiosis associated with gastrointestinal inflammation |
CN103461992A (en) * | 2013-08-05 | 2013-12-25 | 买世禄 | Production method of health care food with characteristics of rich multiple nutrients and diabetes rehabilitation |
-
2014
- 2014-05-21 ES ES201430747A patent/ES2551828B1/en active Active
-
2015
- 2015-05-21 TW TW104116365A patent/TW201600022A/en unknown
- 2015-05-21 NZ NZ726934A patent/NZ726934A/en unknown
- 2015-05-21 UY UY0001036133A patent/UY36133A/en unknown
- 2015-05-21 WO PCT/ES2015/070399 patent/WO2015177393A1/en active Application Filing
- 2015-05-21 AR ARP150101583A patent/AR100545A1/en unknown
- 2015-05-21 AU AU2015263221A patent/AU2015263221B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015263221B2 (en) | 2018-08-09 |
TW201600022A (en) | 2016-01-01 |
UY36133A (en) | 2015-11-30 |
ES2551828B1 (en) | 2016-09-12 |
NZ726934A (en) | 2022-01-28 |
WO2015177393A1 (en) | 2015-11-26 |
ES2551828A1 (en) | 2015-11-23 |
AR100545A1 (en) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008527020A (en) | Novel nutritional supplement composition | |
CN101904507B (en) | Ferrous bisglycinate chelate nutritional composition and application thereof | |
CN104411305A (en) | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance | |
JP6647809B2 (en) | Retinal protective composition | |
AU2015263221B2 (en) | Food compositions comprising tungsten (VI) salts | |
AU2014401750B2 (en) | Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques | |
Franko et al. | Effects of maternal dietary manipulation during different periods of pregnancy on hepatic glucogenic capacity in fetal and pregnant rats near term | |
NZ728467B2 (en) | Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques | |
JP6391959B2 (en) | Non-alcoholic steatohepatitis ameliorating agent and ameliorating nutrition composition | |
ES2639588B1 (en) | Use of a tungsten salt (VI) to promote fertility and normal reproduction in a non-diabetic female mammal | |
Vesco et al. | Maternal nutrient metabolism and requirements in pregnancy | |
Shah et al. | Prospective Role of Unani Pharmacopeial Formulation Safoof Hijrul Yahood in Preventing Recurrence of Nephrolithiasis: An Open Labeled Clinical Study | |
JP2022010027A (en) | Composition for protection of retina | |
JP2023150849A (en) | Corneal epithelial cell proliferation promoter and composition for promoting corneal epithelial cell proliferation, glutathione production promoter in corneal epithelial cells and composition for promoting glutathione production in corneal epithelial cells, and corneal epithelial repair promoter and composition for promoting corneal epithelial repair | |
Underwood | The epidemiology of vitamin A deficiency and depletion (hypovitaminosis A) as a public health problem | |
Coad et al. | Pre-and periconceptual nutrition | |
Cetin et al. | 11 Maternal Micronutrients, Placental Growth, and Fetal Outcome | |
MacGillivray-Fallis | Dietary Factors, Key micronutrients and Nutritional Support | |
Nicholson et al. | Zinc Deficiency and the Eye | |
JP2015059122A (en) | Antioxidant and anti-inflammatory agent using extract of sea urchin test |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |